BioSpace News Archive

Akeso, one of leading Chinese pharmaceutical innovation company announces that the first patient was dosed in a phase I clinical trial of the Company’s independently developed TIGIT monoclonal antibody (AK127) in combination with the Company’s global first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody,AK104) for the treatment of advanced or metastatic solid tumors in Australia.

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), today announced the company will host a conference call and live webcast on Wednesday, Nov. 3, 2021, at 8:00 a.m. ET to report its third quarter 2021 financial results and other business highlights.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data relating to the discovery and optimization of CK-3828136 (CK-136) will be presented at the 2021 Medicinal Chemistry Gordon Research Conference.

Amgen announced that its Board of Directors declared a $1.76 per share dividend for the fourth quarter of 2021.

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Tom Mitro, President and Chief Operating Officer presented an overview on Aerie’s glaucoma franchise at the Ophthalmology Innovation Summit Glaucoma Innovation Showcase.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, announced the appointment of Mark Litton, Ph.D., M.B.A. as Chief Executive Officer of Athira.

Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, announced today that the Company will host a conference call and live webcast on Thursday, November 4, 2021, at 4:30 p.m. Eastern Time.

IVERIC bio, Inc., announced that it is commencing an underwritten public offering of $125.0 million of shares of its common stock.

Puma Biotechnology, Inc., a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, Nov. 4, 2021, following the release of its third quarter 2021 financial results.

Arena Pharmaceuticals, Inc. announced that the Compensation Committee of its Board of Directors granted inducement stock options and inducement restricted stock units to new employees.